BFRI

Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc. (BFRI) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 1.4
EV / EBITDA -2.2
Rev Growth YoY 32.9%
Gross Margin 79.3%
Price Return 3M -60.4%
Price Return 12M -36.0%
Catalyst Signal 0.00
Market Cap $8.5M
TTM Revenue $46.2M
Price / Sales 0.2
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) B (3.4) C+ (2.6) C- (2.0) C+ (2.6) C+ (2.8)
2026-11-10 B (3.4) B (3.5) C+ (2.6) C (2.2) C+ (2.6) B- (2.9)
2026-11-03 B (3.4) B (3.5) C+ (2.6) C (2.2) C+ (2.7) B- (2.9)
2026-10-27 B (3.4) B (3.5) C+ (2.7) C (2.4) C+ (2.6) B- (2.9)
2026-10-20 B (3.4) B (3.5) C+ (2.7) C+ (2.8) C+ (2.6) B- (3.0)
Page 1 of 4